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Background: Podocalyxin (PODXL) is a transmembrane sialomucin, whose aberrant expression and/or allelic
variation associates with poor prognosis and unfavourable clinicopathological characteristics in different cancers.
Membranous expression of PODXL has been suggested to be an independent marker of poor prognosis in
colorectal cancer (CRC), and previously by an in-house monoclonal antibody, we showed that also cytoplasmic
overexpression of PODXL predicts poor prognosis. The aim of this study was to compare two PODXL antibodies
with different epitopes case-by-case in CRC patients.
Methods: Of 840 consecutively operated CRC patients from Helsinki University Central Hospital, PODXL expression
by polyclonal HPA 2110 antibody was evaluated from 780. Associations of PODXL expression with
clinicopathological parameters and the impact of PODXL expression on survival were assessed. Kappa-value was
used to assess the comparability of the two antibodies.
Results: Membranous PODXL expression associated with unfavourable clinicopathological parameters and with
higher risk for disease-specific death from CRC within 5 years (unadjusted hazard ratio (HR) = 1.90; 95% confidence
interval (CI) (1.32-2.75); adjusted HR = 1.64; 95% CI (1.11-2.43)). The comparability of expressions by the two
antibodies was low (kappa =0.219, standard error 0.060, p < 0.0001). Combination of two antibodies identified
a group of patients with even worse prognosis (unadjusted HR = 6.00; 95% CI (3.27-13.0); adjusted HR = 2.14;
95% CI (1.12-4.07)).
Conclusion: Membranous expression by the polyclonal PODXL antibody and cytoplasmic overexpression by
the monocolonal PODXL antibody are both independent markers of poor prognosis, but they recognise
different groups of patients, both of which have poor prognosis. The combined use of the antibodies reveals
a group with an even worse prognosis. The biological reasons for the difference between antibodies warrant
further studies.
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The incidence of colorectal cancer (CRC) is increasing, es-
pecially in the Western world; more than one million new
cases are diagnosed yearly. Even in good series the survival
is about 60%, disease stage at diagnosis being the most
important prognostic factor. To be able to more precisely* Correspondence: tuomas.kaprio@helsinki.fi
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unless otherwise stated.predict outcome of patients we need prognostic factors in
addition to clinicopathological stage [1].
In most countries stage III patients are routinely treated
with adjuvant therapy, which gives a 10% absolute increase
in 5-year survival. The advantage of adjuvant therapy in
stage II patients is not that clear. It would be important to
identify those stage II patients who benefit from postoper-
ative treatment [2].
Podocalyxin-like 1 (PODXL) was originally found in
kidney podocytes [3], but it is also expressed by vascular
[4] and breast epithelium [5], and haematopoietic progeni-
tors [6]. It is an anti-adhesive transmembrane glycoproteinLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Estimated peptide mass for PODXL is 59 kDA, and pros-
translational processing yields a mature glykoprotein of
165 kDA [7]. PODXL is recognised as a stem cell marker
[8], closely related to CD34 and endoglycan. It regulates
cell morphology and adhesion through its connections to
intracellular proteins and to extracellular ligands [9-12].
The role of PODXL in cancer is not fully understood, but
it seems to participate in epithelial-mesenchymal transi-
tion [13], and it interacts with different mediators of
metastasis [10-12,14,15].
In many cancers, such as renal cell carcinoma, breast,
colorectal, urothelial bladder, testicular, and pancreatic
cancer PODXL has been reported to be expressed aber-
rantly and in the first four also to be an independent
marker of poor prognosis [5,10,16-19]. Membranous
PODXL expression has been suggested to correlate with
poor prognosis in CRC and urothelial bladder cancer
[17,18,20]. Germline variants of PODXL was associated
with the development of prostate cancer and also with
the presence of a more aggressive form [14]. The
presence of missense mutations increased the risk for
development of cancer by 50% and an in-frame deletion
was linked to more aggressive tumours [14]. We recently
showed by using a novel monoclonal antibody (mAb)
that high cytoplasmic expression of PODXL is a marker
of poor prognosis in CRC [21].
Because of apparent difference in PODXL expression de-
pending on antibodies used we decided to compare PODXL
expression, by our own in-house HES9 mAb and by a
commercially available polyclonal antibody (pAb) used in
other studies [17,18], case-by-case in a cohort of 840 CRC
patients.
Methods
Patients
The study population comprised 840 consecutive colorectal
cancer patients operated in 1983–2001 at the Department
of Surgery, Helsinki University Central Hospital. The
Finnish Population Register Centre provided follow-
up vital status data needed to compute survival statistics,
and Statistics Finland provided cause of death for all those
deceased. Median age at diagnosis was 66, with a median
follow-up of 5.1 years (range 0–25.8). The 5-year disease-
specific survival rate was 58.9% (95% Cl 55.0-62.8%). This
study was approved by the Surgical Ethics Committee of
Helsinki University Central Hospital (Dnro HUS 226/
E6/06, extension TMK02 §66 17.4.2013) and the National
Supervisory Authority of Welfare and Health (Valvira
Dnro 10041/06.01.03.01/2012).
Preparation of tumour tissue microarrays
Formalin-fixed and paraffin-embedded tumour sam-
ples came from the archives of Department of Pathology,Helsinki University Central Hospital. Representative areas
of tumour samples on haematoxylin- and eosin-stained
tumour slides were marked by an experienced pathologist.
Three 1.0-mm-diameter punches taken from each sample
were mounted on recipient paraffin block with a semiau-
tomatic tissue microarray instrument (TMA) (Beecher
Instruments, Silver Spring, MD, USA) as described [22].
Antibodies
The monoclonal in-house antibody (HES9) recognises
amino acid residues 189–192 of PODXL. The polyclonal
antibody (HPA 2110, Atlas Antibodies, Stockholm, Sweden)
recognises amino acid residues 278–415 of PODXL. Both
epitopes are in the extracellular part of PODXL. Of four
protein coding PODXL splice variants, the epitope se-
quence of the pAb matches three with 100% (PODXL 001,
005, and 201, The Human Protein Atlas). The fourth
splice variant matches with 87% (PODXL 202). The epi-
tope sequence of the mAb HES9 matches all splice vari-
ants with 100%. The antibodies have been described in
detail [21,23,24].
Immunohistochemistry
TMA-blocks were freshly cut into 4-μm sections. After
deparaffinization in xylene and rehydration through a
gradually decreasing concentration of ethanol to distilled
water, slides were treated in a PreTreatment module (Lab
Vision Corp., Fremont, CA, USA) in Tris–HCl (pH 8.5)
buffer for 20 minutes at 98°C for antigen retrieval. For the
staining procedure by the Dako REAL EnVision Detection
system, Peroxidase/DAB+, Rabbit/Mouse (Dako, Glostrup,
Denmark) an Autostainer 480 (Lab Vision) was used.
Tissues were incubated with the mAb (dilution 1:500 =
5 μg/ml) or pAb (dilution 1:250) for one hour at room
temperature. In every staining series renal tissue served as
positive control.
Scoring of samples
As reported PODXL expression by the HES9 mAb was
cytoplasmic and often granular. Positivity in tumour cells
was uniform, with no nuclear expression [21]. By the pAb
PODXL expression was cytoplasmic, with no nuclear ex-
pression. In some cases there were a distinct membranous
positivity, even with weak cytoplasmic positivity. For the
mAb negative cytoplasmic staining was scored as 0,
weakly positive as 1, moderately positive as 2, and strongly
positive as 3. For the pAb cytoplasmic staining was scored
0–2 (negative-moderate-strong) and in case of distinct
membranous staining as 3, regardless of the intensity of
the cytoplasmic staining [17]. Stainings were scored inde-
pendently by T.K. and J.H., who were blinded to clinical
data and outcome. Differences in scoring were discussed
until consensus.
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For statistical purposes, categories of PODXL expression
were dichotomised into low (0–2) and high (3) for the
mAb and into non-membranous (0–2) and membranous
(3) for the pAb. To study the two antibodies together a
categorization with three classes was created; low (mAb:
low and pAb: non-membranous), moderate (either mAb:
high or pAb: membranous), and high (mAb: high and
pAb: membranous). The antibodies were also categorized
as weak (mAb: low and pAb: non-membranous) and
strong (mAb: high and/or pAb: membranous). Evaluation
of the association between PODXL expression and clinico-
pathological parameters was done by the Fisher exact-test
or the linear-by-linear association test for ordered parame-
ters. Kappa-value was used for testing the concordance of
PODXL expression according to mAb and pAb. Disease-
specific overall survival was counted from date of surgery
to date of death from colorectal cancer, or until end of
follow-up. Survival analysis was done by the Kaplan-Meier
method and compared by the log rank test. The Cox
regression proportional hazard model served for uni- and
multivariable survival analysis, adjusted for sex, age, Dukes
classification, and differentiation. Testing of the Cox model
assumption of constant hazard ratios over time involved
the inclusion of a time-dependent covariate separately for
each testable variable. Hazard ratios of differentiation and
Dukes class D were analyzed in two periods (0 to 1.25 and
1.25 to 5 years) in order to meet the assumptions of the
Cox model, and the time-dependent Cox model was
used. Interaction terms were considered, but no signifi-
cant interactions were found. All tests were two-sided. A
p-value of 0.05 was considered significant. All statistical
analyses were done with SPSS version 20.0 (IBM SPSS
Statistics, version 20.0 for Mac; SPSS, Inc., Chicago, IL,
USA, an IBM Company).CBA
Figure 1 Immunohistochemical staining pattern of PODXL by polyclo
in colorectal cancer. (A) PODXL-negative, (B) moderate cytoplasmic positiv
immunoreactivity. Original magnification was × 40.Results
Immunohistochemical staining by the polyclonal
antibody
PODXL expression by the pAb was cytoplasmic in tumour
cells, but in some cases a distinct membranous expression
was seen, which did not always correlate with intensity of
cytoplasmic expression. Such distinct membranous stain-
ing was not seen with the mAb HES9 [21].
Of 840 tumours represented in the TMA, PODXL
staining with pAb could be evaluated in 780 (92.6%); 46
(5.9%) had no cytoplasmic positivity, 322 (41.2%) showed
moderate cytoplasmic staining, 349 (44.7%) strong cyto-
plasmic staining, and 63 (8.1%) positive staining with
distinctive membranous staining. Representative images
of pAb stainings are shown in Figure 1. Comparative im-
ages of high cytoplasmic staining by the mAb and mem-
branous staining by the pAb in same tumours are shown
in Figure 2. The staining results by the mAb HES9 have
been described previously [21].
Association of PODXL expression with clinicopathological
parameters
There was a strong association between membranous
PODXL expression and poor differentiation (p < 0.0001)
and advanced stage (p < 0.001). Membranous PODXL
expression did not associate with age, gender, tumour
location (right vs left hemicolon or colon vs rectum), or
tumour histology (Table 1). The corresponding results for
the mAb HES9 have been described [21].
Comparison of PODXL expression by mono- and polyclonal
antibodies
The agreement of expression of the two antibodies across
cases was low (kappa-value = 0.219, standard error 0.060,
p < 0.0001) using dichotomous values for both antibodies.D
nal antibody HPA 2110. Representative images of PODXL expression
ity, (C) strong cytoplasmic positivity, and (D) positive membranous
CB
D
A
E F
Figure 2 Case-by-case comparison of immunohistochemical
stainings by monoclonal antibody HES9 and polyclonal
antibody HPA 2110 in colorectal cance. Comparative images of
three colorectal cancer tumour samples with membranous staining
pattern by the polyclonal antibody (A, C, E) or strong cytoplasmic
positivity by the monoclonal antibody (B, D, F).
Table 1 Association of PODXL expression and
clinicopathological parameters by polyclonal antibody
HPA 2110
PODXL expression
Non-membranous Membranous
n (%) 717 (91.9) 63 (8.1) p-value
Age, years
<65 299 (41.7) 32 (50.8) 0.184
≥ 65 418 (48.3) 31 (49.2)
Gender
Male 398 (55.5) 31 (49.2) 0.357
Female 319 (44.5) 32 (50.8)
Dukes
A 111 (15.5) 2 (3.2) < 0.001
B 258 (36.0) 17 (27.0)
C 191 (26.6) 22 (34.9)
D 157 (21.9) 22 (34.9)
Grade (WHO)
1 27 (3.8) 0 (0) < 0.0001
2 511 (71.8) 27 (42.9)
3 155 (21.8) 30 (47.6)
4 19 (2.7) 6 (9.5)
Missing 5
Location
Colon 370 (51.6) 35 (55.6) 0.548
Rectum 347 (48.4) 28 (44.4)
Side
Right 193 (26.9) 21 (33.3) 0.274
Left 542 (73.1) 42 (66.7)
Histology
Adenomatous 644 (89.9) 57 (90.5) 1.000
Mucinous 72 (10.1) 6 (9.5)
Missing 1
Fisher exact-test was used for 2 × 2 tables and linear-by-linear association
test for tables with more than two rows. Missing data is not included in
the analyses.
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membranous staining by pAb (n = 63) only 14 tumours
were shared.
Association of PODXL expression with clinicopathological
parameters by monoclonal and polyclonal antibodies
combined
Analysis of combined PODXL expression (low-moderate-
high categories) with clinicopathological parameters showed
significant associations between high PODXL expressionand poor differentiation (p < 0.0001), advanced stage (p <
0.0001), and tumour side (p = 0.003). High expression did
not associate with age, gender, tumour location (colon vs
rectum), nor with tumour histology (Table 2). Association
of the clinicopathological parameters with the strong
PODXL expression (weak-strong categories) were similar
(data not shown).
Survival analysis
For colorectal cancer patients with membranous PODXL
expression by polyclonal antibody disease-specific sur-
vival (DSS) was significantly poorer (p = 0.001). Five-year
DSS was 40.5% (95% CI 27.4-53.6%) for patients with
Table 2 Association of clinicopathological parameters
and PODXL expression by polyclonal and monoclonal
antibodies combined
PODXL expression
Low Moderate High
n (%) 714 (88.4) 79 (9.8) 14 (1.7) p-value
Age, years
<65 300 (42.0) 38 (48.1) 5 (35.7) 0.643
≥ 65 414 (58.0) 41 (51.9) 9 (64.3)
Gender
Male 398 (55.7) 41 (51.9) 7 (50.0) 0.450
Female 316 (44.3) 38 (48.1) 7 (50.0)
Dukes
A 113 (15.8) 4 (5.1) 0 (0.0) < 0.0001
B 257 (36.0) 26 (32.9) 2 (14.3)
C 187 (26.2) 32 (40.5) 2 (14.3)
D 157 (22.0) 17 (21.5) 10 (71.4)
Grade (WHO)
1 28 (3.9) 0 (0.0) 0 < 0.0001
2 513 (72.4) 32 (40.5) 3 (21.4)
3 149 (21.0) 37 (46.8) 9 (64.3)
4 19 (2.7) 10 (12.7) 2 (14.3)
Missing 5
Location
Colon 362 (50.7) 49 (62.0) 7 (50.0) 0.168
Rectum 352 (49.3) 30 (38.0) 7 (50.0)
Side
Right 185 (25.9) 32 (40.5) 6 (42.9) 0.003
Left 529 (74.1) 47 (59.5) 8 (57.1)
Histology
Adenomatous 639 (89.6) 70 (88.6) 13 (92.9) 0.879
Mucinous 74 (10.4) 9 (11.4) 1 (7.1)
Missing 1
Linear-by-linear association test was used for this table. Missing data is not
included in the analyses.
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Figure 3 Membranous PODXL expression by polyclonal
antibody HPA 2110 is a marker of poor prognosis in colorectal
cancer. Disease-specific survival analysis according to the Kaplan-
Meier method for membranous PODXL expression by the polyclonal
antibody HPA 2110 in colorectal cancer. Log-rank test was
used here.
Kaprio et al. BMC Cancer 2014, 14:494 Page 5 of 8
http://www.biomedcentral.com/1471-2407/14/494membranous PODXL expression compared to 60.0% (95%
CI 56.3-63.7%) for non-membranous expression (Figure 3).
Results were similar for the combination of pAb and mAb
(weak-strong), but the group with poor prognosis was
larger (n = 93 vs 63) (data not shown).
Combination (low-moderate-high) of mAb and pAb
showed a significantly poorer DSS for colorectal cancer
patients with high expression compared to low expression
(p < 0.0001) or moderate expression (p < 0.0001). No sta-
tistically significant difference in DSS was seen between
those with low and moderate expression (p = 0.24). Five-
year DSS for CRC patients with low expression was 60.3%
(95% CI 56.6-64.0%), for those with moderate expression52.8% (95% CI 41.0-64.6%),and for those with high expres-
sion 8.3% (95% CI −7.4-24.0%) (Figure 4).
Cox regression univariable analysis confirmed these
results. In multivariable survival analyses adjusted for age,
gender, Dukes classification, and differentiation grade,
membranous PODXL expression by the pAb remained
statistically significant. Also the combined high expression
of PODXL using mAb and pAb remained statistically
significant in multivariable analysis (Table 3).Discussion
Here we show that membranous PODXL expression by
the pAb is an independent marker of poor prognosis in
CRC. We also show that the case-by-case expression of
PODXL by mAb HES9 and pAb HPA 2110 do not correl-
ate, even though their prognostic profile and association
with clinicopathological parameters (except for tumour
side) is similar. Combination of the results of both anti-
bodies enlarges the group of patients with poor prognosis
compared to the use of a single antibody and revealed a
group with an even worse prognosis.
As an anti-adhesive molecule, aberrant PODXL
expression has been suggested to support the disruption
of cell-to-cell and cell-to-extracellular matrix adhesions,
thus promoting tumour dissemination [15]. Its ectopic
expression has been shown to correlate with increased
invasion in breast and prostate cancer [25]. Membran-
ous PODXL expression by the polyclonal antibody HPA
2210 correlates with poor differentiation, advanced
Years after operation
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Figure 4 Concomitant positivity by two PODXL antibodies
identifies a group with very poor prognosis. Disease-specific
survival analysis according to the Kaplan-Meier method for combined
expression of PODXL by polyclonal antibody HPA 2110 and monoclonal
antibody HES9. Concomitant membranous positivity by the polyclonal
antibody and high cytoplasmic positivity by the monoclonal antibody
identifies a group with an even worse prognosis in colorectal cancer.
Global log-rank was the test used here.
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results confirm these findings. The results are similar,
except for tumour side, to those obtained by monoclonal
antibody HES9 in the same patient cohort.
Even though the two antibodies were known to recog-
nise different epitopes within the extracellular portion of
the PODXL molecule, it was surprising that their ex-
pression patterns varied and that case-by-case expres-
sions were not uniform. It is possible that these two
antibodies describe a slightly different biological phase
of PODXL in CRC. This hypothesis is supported by the
finding that patients with concomitant high cytoplasmic
PODXL expression by the mAb and membranous ex-
pression by the pAb had an even worse DSS compared
to those with only membranous or only high cyto-
plasmic PODXL expression. Over 70% of patients with
concomitant positivity had metastatic disease and the five-
year DSS was as low as 8.3%, with one-year DSS of 25.0%.
The high proportion of metastasised cancers in this group
supports the role of PODXL overexpression in tumour
cell dissemination leading to metastases to distant organs.
We hypothesise that the polyclonal antibody recognises
an active form of PODXL at the cell membrane, whereas
the monoclonal antibody with its smaller target epitope is
able to recognise overexpression of cytoplasmic PODXL,
that either has a function in the cytoplasm, or is movingtowards the cell membrane. Another possibility is that
these antibodies recognise different variants of PODXL.
Since expression by these two antibodies seems to de-
scribe different of PODXL function, their combination
provides synergy in predicting outcome.
There was no clear difference between the two anti-
bodies as prognostic markers, as their hazard ratios for
the 5-year risk of death were almost the same, with both
remaining independent prognostic factors in multivari-
able analysis. The staining differences were clearer by the
mAb and were easier to score than by the pAb. The pAb
recognised a slightly larger group of patients with poor
prognosis than the mAb. By the pAb there was no differ-
ence in expression between right- or left sided tumours,
which we saw by the mAb [21]. This may be due to a dif-
ferent cytoplasmic activity of PODXL in left- compared
to right-sided tumours. Verification of our finding by
the mAb requires validation in other CRC patient cohorts.
Moreover, further experiments on PODXL’s behaviour
in CRC are needed to define the reason for this differ-
ence in expression between the antibodies and its
biological background.
The proportion of membranous positivity by the pAb
and the staining was obviously similar, to that of other
studies on CRC and also its association to DSS and to
clinicopathological parameters is corresponding [17,20].
Although the case-by-case expression differs between
pAb and mAb there was no difference in association be-
tween PODXL and DSS nor with clinicopathological pa-
rameters. This supports the theory that also cytoplasmic
overexpression of PODXL and not only membranous
expression is a marker of poor prognosis.
The strength of this study is a well-characterised and
a large patient cohort, with a long follow-up time.
The TMA technique allows analysis of such large pa-
tient cohorts. Previously, the staining of PODXL in TMA-
sections versus whole tissue was shown to be uniform
[17], which eliminates the issue of investigating only a
small proportion of the tumours by the TMA technique.
Unfortunately, during the production and staining of
the TMA:s 7.4% of tissue samples were lost due to tech-
nical reasons.
The different expression patterns of the two antibodies
offer a possibility for their combined use. A simple com-
bination of the expressions created two new groups; one
with low cytoplasmic/non-membranous and other with
high cytoplasmic and/or membranous expression. This
defined a larger number of patients with poor prognosis,
than either antibody alone.
When combining the expression patterns into three
new classes, we were able to identify a small group of
patients with a grim prognosis. The size of this group was
small, and thus this phenomenon is more of biological
interest than of clinical value.
Table 3 Cox uni-and multivariable analysis of relative risk of death from colorectal cancer within 5 years by PODXL expression
Polyclonal antibody Monoclonal antibody Combined
PODXL expression HR (95% CI) P-value N (events) PODXL expression HR (95% CI) P-value N (events) PODXL expression HR (95% CI) P-value N (events)
Univariable Univariable Univariable
Non-membranous 1.00 717 (266) Low 1.00 723 (266) Low 1.00 714 (261)
Membranous 1.90 (1.32-2.75) 0.001 63 (32) High 2.00 (1.31-3.06) 0.001 44 (23) Moderate 1.38 (0.96-1.97) 0.084 79 (33)
High 6.00 (3.27-13.0) < 0.001 14 (11)
Multivariable Multivariable Multivariable
Non-membranous 1.00 712 (266) Low 1.00 719 (266) Low 1.00 709 (261)
Membranous 1.64 (1.11-2.43) 0.012 63 (32) High 1.82 (1.15-2.86) 0.01 44 (23) Moderate 1.63 (1.11-2.39) 0.012 79 (33)
High 2.14 (1.12-4.07) 0.021 14 (11)
Abbreviations: CI confidence interval, HR Hazard ratio. Multivariable analysis included adjustment for gender, age (>/≤65 years), Dukes class, differentiation grade (G1/2 vs G3/4). Results of the monoclonal antibody
alone have been reported previously [21].
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PODXL is an independent marker of poor prognosis in
colorectal cancer. Not only membranous expression of
PODXL by a polyclonal antibody (HPA 2110) shown
here and in previous reports, but also high cytoplasmic
expression of PODXL by monoclonal antibody (HES9)
defines a group with poor prognosis. Combination of
two antibodies defines a larger number of patients with
poor prognosis and also a small group of patients with
an even worse prognosis. This provides clues for the
function of PODXL in CRC. The different expression
patterns of the two antibodies suggests that they either
recognise different variants of PODXL in colorectal can-
cer cells or that the antibodies catch PODXL at different
stage on its way from cytoplasm to cellular membrane.
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